4D Pharma on their Merger & Intention to seek NASDAQ Listing plus Chris Bailey on 4 Large Caps
If you find this podcast useful please give it a rating and review on iTunes by clicking here
Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here: www.VoxMarkets.co.uk/app
On today's Vox Markets Podcast: 4D Pharma on their Merger & Intention to seek NASDAQ Listing plus Chris Bailey on 4 Large Caps and Chris Bailey on 4 Large Caps
Duncan Peyton, Chief Executive Officer of 4D Pharma #DDDD explains the reasons behind their merger and intention to seek a NASDAQ listing.
Founded in February 2014, 4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx®, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.
Chris Bailey founder of Financial Orbit covers news from the following companies:
GSK #GSK
Unilever #ULVR
International Consolidated Airlines #IAG
RELX #REL
(Interview starts at 11 minutes 29 seconds)
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.